José María Mir-Bonafé
Research Subjects
José María Mir-Bonafé has a total of 47 co-authors. Here are the top co-authors by number of shared publications:
Juan Ferrando
Department of Dermatology, Hospital Clinic, University of Barcelona, Spain
24 shared publicationsAndrea Combalía
Department of Dermatology, Hospital Clinic, University of Barcelona, Spain
12 shared publicationsEmilia Fernández-López
Dermatology, and
5 shared publications- Angel Santos-Briz
Department of Pathology, Hospital Universitario de Salamanca, Salamanca, Spain
3 shared publications - Javier Cañueto
Department of Dermatology, Complejo Asistencial Universitario de Salamanca (CAUSA) and Instituto de Investigación Biomédica of Salamanca (IBSAL) and Faculty of Medicine, University of Salamanca, Salamanca, Spain
3 shared publications M. Mir-Bonafé
TricologiaMir, Unidad de Tricología y Trasplante Capilar, Palma de Mallorca, Spain
3 shared publications
Latest Publications
- Open Access
- 24 June 2026
- Published by Elsevier in Actas Dermo-Sifiliograficas
- Vol. 117 (10) , 104699
“Preview Long Hair FUE” Technique in Eyebrow Transplantation
- 24 June 2026
- Published by Elsevier in Actas Dermo-Sifiliograficas
- Vol. 117 (10) , 104699
Open Access“Preview Long Hair FUE” Technique in Eyebrow Transplantation
- Open Access
- 9 March 2026
- Published by Elsevier in Actas Dermo-Sifiliograficas
- Vol. 117 (6) , 104601
Mirror Hair Transplantation: Donor and Recipient Area Exchange in Discoid Lupus
- 9 March 2026
- Published by Elsevier in Actas Dermo-Sifiliograficas
- Vol. 117 (6) , 104601
Open AccessMirror Hair Transplantation: Donor and Recipient Area Exchange in Discoid Lupus
- 27 March 2024
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 38 (11) , e923-e925
‘Vasculitis‐like’ damage due to micropunch in follicular unit excision hair transplantation surgery: Ten cases
- 27 March 2024
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 38 (11) , e923-e925
‘Vasculitis‐like’ damage due to micropunch in follicular unit excision hair transplantation surgery: Ten cases
- 26 June 2023
- Published by H1 Connect
Faculty Opinions recommendation of Mesotherapy with Bicalutamide: A New Treatment for Androgenetic Alopecia.
Female pattern hair loss (FPHL) is the most common form of alopecia in women. Medical therapy is mainly based on antiandrogens and minoxidil. The vast majority of them have been tested in mesotherapy, except for bicalutamide, a selective androgen receptor antagonist. The authors of this innovative study show their experience treating FPHL with bicalutamide, for the first time, in mesotherapy. Six premenopausal women were included (mean age: 35.7 years and clinical diagnosis of Olsen Grade: II or III). All were treated with 1ml bicalutamide 0.5% mesotherapy in 3 monthly sessions. Clinical images were taken at baseline, after the third session, and 6 months after the first session. The images were evaluated by two independent dermatologists specializing in trichology. Interestingly, an improvement in hair density was described after this third session. However, it is also remarkable that the degree of alopecia was not modified in any of the cases. All patients stated that hair density and seborrhea had improved after 3 months of treatment (overall satisfaction: 6.3). In conclusion, this novel study showed that “bicalutamide mesotherapy was well tolerated and welcomed by the patients,” as stated by the authors.
- 26 June 2023
- Published by H1 Connect
Faculty Opinions recommendation of Mesotherapy with Bicalutamide: A New Treatment for Androgenetic Alopecia.
Female pattern hair loss (FPHL) is the most common form of alopecia in women. Medical therapy is mainly based on antiandrogens and minoxidil. The vast majority of them have been tested in mesotherapy, except for bicalutamide, a selective androgen receptor antagonist. The authors of this innovative study show their experience treating FPHL with bicalutamide, for the first time, in mesotherapy. Six premenopausal women were included (mean age: 35.7 years and clinical diagnosis of Olsen Grade: II or III). All were treated with 1ml bicalutamide 0.5% mesotherapy in 3 monthly sessions. Clinical images were taken at baseline, after the third session, and 6 months after the first session. The images were evaluated by two independent dermatologists specializing in trichology. Interestingly, an improvement in hair density was described after this third session. However, it is also remarkable that the degree of alopecia was not modified in any of the cases. All patients stated that hair density and seborrhea had improved after 3 months of treatment (overall satisfaction: 6.3). In conclusion, this novel study showed that “bicalutamide mesotherapy was well tolerated and welcomed by the patients,” as stated by the authors.
- Open Access
- 20 April 2023
- Published by Elsevier in Actas Dermo-Sifiliograficas
- Vol. 114 (5) , T437-T441
[Translated article] Immediate-Onset Linear Effluvium Associated With High-Density Hair Transplantation: A Series of 28 Case
- 20 April 2023
- Published by Elsevier in Actas Dermo-Sifiliograficas
- Vol. 114 (5) , T437-T441
Open Access[Translated article] Immediate-Onset Linear Effluvium Associated With High-Density Hair Transplantation: A Series of 28 Case
- Open Access
- 3 March 2023
- Published by Elsevier in Actas Dermo-Sifiliograficas
- Vol. 114 (5) , 437-441
Efluvio en línea de aparición inmediata asociado a trasplante capilar de alta densidad: descripción de 28 casos
- 3 March 2023
- Published by Elsevier in Actas Dermo-Sifiliograficas
- Vol. 114 (5) , 437-441
Open AccessEfluvio en línea de aparición inmediata asociado a trasplante capilar de alta densidad: descripción de 28 casos
- 13 December 2022
- Published by H1 Connect
Faculty Opinions recommendation of Efficacy and safety of topical finasteride spray solution for male androgenetic alopecia: a phase III, randomized, controlled clinical trial.
Finasteride is an FDA-approved pharmacologic agent for treating benign prostate hyperplasia and androgenic alopecia (AGA) in men. Topical finasteride, while not FDA-approved, theoretically lacks the systemic adverse effects associated with oral finasteride. Piraccini and colleagues from the Topical Finasteride Study Group conducted this phase III, randomized, controlled clinical trial to evaluate efficacy and safety of topical finasteride compared with placebo, and to analyse systemic exposure and overall benefit compared with oral finasteride. The study lasted 24 weeks in adult male outpatients with AGA at 45 centres in Europe. Finasteride, testosterone and dihydrotestosterone (DHT) concentrations were measured. Efficacy: Of 458 randomized patients, target area hair count was significantly greater with topical finasteride than placebo. In addition, in our opinion, it is highly interesting that it was numerically similar between topical and oral finasteride. Safety: Incidence and causes of discontinuation did not differ meaningfully between topical finasteride and placebo. No serious adverse events were treatment-related. We also quote from the manuscript this very remarkable paragraph: “As maximum plasma finasteride concentrations were >100 times lower, and reduction from baseline in mean serum DHT concentration was lower (34.5 vs. 55.6%), with topical vs. oral finasteride, there is less likelihood of systemic adverse reactions of a sexual nature related to a decrease in DHT with topical finasteride.” In conclusion, topical finasteride represents a newly studied, optimistic option for the management of AGA, with an excellent safety profile. We would also like to point out that further studies are necessary to confirm that the efficacy of both topical and oral forms of finasteride may reach the high similarity presented by these researchers.
- 13 December 2022
- Published by H1 Connect
Faculty Opinions recommendation of Efficacy and safety of topical finasteride spray solution for male androgenetic alopecia: a phase III, randomized, controlled clinical trial.
Finasteride is an FDA-approved pharmacologic agent for treating benign prostate hyperplasia and androgenic alopecia (AGA) in men. Topical finasteride, while not FDA-approved, theoretically lacks the systemic adverse effects associated with oral finasteride. Piraccini and colleagues from the Topical Finasteride Study Group conducted this phase III, randomized, controlled clinical trial to evaluate efficacy and safety of topical finasteride compared with placebo, and to analyse systemic exposure and overall benefit compared with oral finasteride. The study lasted 24 weeks in adult male outpatients with AGA at 45 centres in Europe. Finasteride, testosterone and dihydrotestosterone (DHT) concentrations were measured. Efficacy: Of 458 randomized patients, target area hair count was significantly greater with topical finasteride than placebo. In addition, in our opinion, it is highly interesting that it was numerically similar between topical and oral finasteride. Safety: Incidence and causes of discontinuation did not differ meaningfully between topical finasteride and placebo. No serious adverse events were treatment-related. We also quote from the manuscript this very remarkable paragraph: “As maximum plasma finasteride concentrations were >100 times lower, and reduction from baseline in mean serum DHT concentration was lower (34.5 vs. 55.6%), with topical vs. oral finasteride, there is less likelihood of systemic adverse reactions of a sexual nature related to a decrease in DHT with topical finasteride.” In conclusion, topical finasteride represents a newly studied, optimistic option for the management of AGA, with an excellent safety profile. We would also like to point out that further studies are necessary to confirm that the efficacy of both topical and oral forms of finasteride may reach the high similarity presented by these researchers.
- 3 October 2022
- Published by H1 Connect
Faculty Opinions recommendation of There Is a Positive Dose-Dependent Association between Low-Dose Oral Minoxidil and Its Efficacy for Androgenetic Alopecia: Findings from a Systematic Review with Meta-Regression Analyses.
Recently, low-dose oral minoxidil (LDOM) has entered the landscape of therapies for androgenetic alopecia (AGA). This study is the first to show a positive dose-dependent association between the use of LDOM and change in hair diameter, hair density, risk of hypertrichosis, and cardiovascular adverse events for persons with AGA. Future randomized trials could produce causal evidence that would corroborate these dose-dependent associations.
- 3 October 2022
- Published by H1 Connect
Faculty Opinions recommendation of There Is a Positive Dose-Dependent Association between Low-Dose Oral Minoxidil and Its Efficacy for Androgenetic Alopecia: Findings from a Systematic Review with Meta-Regression Analyses.
Recently, low-dose oral minoxidil (LDOM) has entered the landscape of therapies for androgenetic alopecia (AGA). This study is the first to show a positive dose-dependent association between the use of LDOM and change in hair diameter, hair density, risk of hypertrichosis, and cardiovascular adverse events for persons with AGA. Future randomized trials could produce causal evidence that would corroborate these dose-dependent associations.
- 1 August 2022
- Published by H1 Connect
Faculty Opinions recommendation of Mesotherapy with dutasteride for androgenetic alopecia: A retrospective study in real clinical practice.
Mesotherapy with dutasteride (MD) has been proposed as an effective method to improve hair loss. In addition, this locally injected therapy adds the advantage of reducing systemic absorption, in contrast to the oral posology of dutasteride. The aim of this retrospective work was to study its effectiveness and security. We recommend this publication because of its comparability with real clinical practice. The most interesting issue is that, of a total of 541 patients included, 86 patients (15.9%) received MD as monotherapy for at least one year. And we would like to focus this recommendation on the results of these 86 patients; clinical improvement was observed in 71 of them (86.6%), with 33 of those patients presenting a marked improvement. There are other remarkable general points stated by the authors; factors related to a better response are women (vs. men), older ages, and intervals of injections of 3 months (vs. longer). We are surprised with this women-related better response, which divergences from what we previously believed. The most frequent side effect is, as already known, pain. Severe adverse effects were absent. In conclusion, we recommend this article as it is comparable with our real daily practice. Remarkably, the vast majority of patients treated with MD as a monotherapy presented with clinical improvement with no severe secondary effects.
- 1 August 2022
- Published by H1 Connect
Faculty Opinions recommendation of Mesotherapy with dutasteride for androgenetic alopecia: A retrospective study in real clinical practice.
Mesotherapy with dutasteride (MD) has been proposed as an effective method to improve hair loss. In addition, this locally injected therapy adds the advantage of reducing systemic absorption, in contrast to the oral posology of dutasteride. The aim of this retrospective work was to study its effectiveness and security. We recommend this publication because of its comparability with real clinical practice. The most interesting issue is that, of a total of 541 patients included, 86 patients (15.9%) received MD as monotherapy for at least one year. And we would like to focus this recommendation on the results of these 86 patients; clinical improvement was observed in 71 of them (86.6%), with 33 of those patients presenting a marked improvement. There are other remarkable general points stated by the authors; factors related to a better response are women (vs. men), older ages, and intervals of injections of 3 months (vs. longer). We are surprised with this women-related better response, which divergences from what we previously believed. The most frequent side effect is, as already known, pain. Severe adverse effects were absent. In conclusion, we recommend this article as it is comparable with our real daily practice. Remarkably, the vast majority of patients treated with MD as a monotherapy presented with clinical improvement with no severe secondary effects.
- 9 February 2022
- Published by H1 Connect
Faculty Opinions recommendation of Review of oral minoxidil as treatment of hair disorders: in search of the perfect dose.
Oral minoxidil was not used for alopecia in the past because of its dose-related adverse effects; usually, a dose of 10-40mg daily is given for hypertension. The use of low-dose oral minoxidil (LDOM) overcomes this limitation and has become popular for its efficacy and safety. It has become a true revolution within the alopecia-related field. The authors performed a systematic review of LDOM therapy to assess its efficacy and safety in the treatment of various hair diseases. Women received 0.25-2mg of LDOM in the published series. Hypertrichosis, the most common secondary effect, was observed in 17-27% of women, depending on the series. It is a dose-related, reversible, and normally mild complication. LDOM treatment was also studied in males. A dosage of 2.5-5mg/day was usually given. Hypertrichosis, lower limb oedema, and hair shedding were more common with the 5mg than the 2.5mg dosage. While a dose of 0.25mg/day revealed no significant improvement, other authors stated that 1.25mg/day improved most cases, although higher doses may be required if the response is suboptimal following 6 months of treatment. Finally, 100% of patients receiving under 5mg/day presented with marked improvement. Of note, the vast majority of males included in this series accompanied this improvement with face and forearm hypertrichosis. In female patients with chronic telogen effluvium, a mean dosage of 1mg/day was associated with improvement after 6 and 12 months of treatment. On the other hand, few studies concerning other forms of alopecia such as alopecia areata, lichen planopilaris, frontal fibrosing alopecia, permanent chemotherapy-induced alopecia (only one case), or few hair shaft disorders showed an improvement of general hair thickness and density. LDOM is an emerging therapy for alopecia, characterized by its good safety profile and few contraindications that allow it to be prescribed for most patients. The available literature suggests that women require lower doses, from 0.25-2.5mg daily, while men require higher doses for maximal efficacy, from 1.25-5mg daily. Adverse effects are related to higher doses. A better understanding of the long-term adverse events and duration of therapy is needed to provide general conclusions.
- 9 February 2022
- Published by H1 Connect
Faculty Opinions recommendation of Review of oral minoxidil as treatment of hair disorders: in search of the perfect dose.
Oral minoxidil was not used for alopecia in the past because of its dose-related adverse effects; usually, a dose of 10-40mg daily is given for hypertension. The use of low-dose oral minoxidil (LDOM) overcomes this limitation and has become popular for its efficacy and safety. It has become a true revolution within the alopecia-related field. The authors performed a systematic review of LDOM therapy to assess its efficacy and safety in the treatment of various hair diseases. Women received 0.25-2mg of LDOM in the published series. Hypertrichosis, the most common secondary effect, was observed in 17-27% of women, depending on the series. It is a dose-related, reversible, and normally mild complication. LDOM treatment was also studied in males. A dosage of 2.5-5mg/day was usually given. Hypertrichosis, lower limb oedema, and hair shedding were more common with the 5mg than the 2.5mg dosage. While a dose of 0.25mg/day revealed no significant improvement, other authors stated that 1.25mg/day improved most cases, although higher doses may be required if the response is suboptimal following 6 months of treatment. Finally, 100% of patients receiving under 5mg/day presented with marked improvement. Of note, the vast majority of males included in this series accompanied this improvement with face and forearm hypertrichosis. In female patients with chronic telogen effluvium, a mean dosage of 1mg/day was associated with improvement after 6 and 12 months of treatment. On the other hand, few studies concerning other forms of alopecia such as alopecia areata, lichen planopilaris, frontal fibrosing alopecia, permanent chemotherapy-induced alopecia (only one case), or few hair shaft disorders showed an improvement of general hair thickness and density. LDOM is an emerging therapy for alopecia, characterized by its good safety profile and few contraindications that allow it to be prescribed for most patients. The available literature suggests that women require lower doses, from 0.25-2.5mg daily, while men require higher doses for maximal efficacy, from 1.25-5mg daily. Adverse effects are related to higher doses. A better understanding of the long-term adverse events and duration of therapy is needed to provide general conclusions.